CatalystMarker
← board

GRMLW

distress 7/10 · high distress / dilution risk
$0.13-26%today-36% from 52w high
greenlandmines.com5 employeesCharlotte, NC
Lead: amyotrophic lateral sclerosis
Revenue
pre-revenue
Liquidity
$10M
Runway
1.1 yrs
Shares 1y
+98%

Price & events

-30.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-25.5%
1D
-26.8%
1W
1M
3M
6M
1Y
2Y
5Y
-30.1%
All

Overview

Market Cap
$16.29M
Volume
1.44K
52 Week Range
$0.13 – $0.21
Total Shares
121.24M
Float Shares
100.34M
RVOL
0.07x
Beta
2.52

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 121,238,660 · 6 offerings/1y · 5 PIPEs
  • 2026-06-258-Kprivate_placement
  • 2026-06-228-Kprivate_placement
  • 2026-06-22424B3offering
  • 2026-06-178-Kmaterial_agreement
  • 2026-05-218-Kmaterial_agreement
  • 2026-03-108-Kprivate_placement
  • 2026-03-028-Kprivate_placement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — amyotrophic lateral sclerosis

  • NVSEFNOVARTIS AG$292.0B · D3
  • ARGXARGENX SE$54.3B · D0
  • BIIBBIOGEN INC.$29.2B · D2
  • ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
  • CORTCORCEPT THERAPEUTICS INC$10.0B · D0
  • QUREuniQure N.V.$2.5B · D5
  • COYACoya Therapeutics, Inc.$101M · D3
  • LONALeonaBio, Inc.$71M · D6
  • MNOVMEDICINOVA INC$65M · D1
  • BCLIBRAINSTORM CELL THERAPEUTICS INC.$12M · D8

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.